The invisible scaffold…with invisible benefits?

Catheter Cardiovasc Interv. 2017 Jun 1;89(7):1139-1140. doi: 10.1002/ccd.27148.

Abstract

Authors suggest the use of an investigator-owned and directed, prospective, non-randomized, single-arm multicenter registry at 23 Italian hospitals to follow 500 STEMI patients who receive BVS. Follow-up of patients is out to 5 years to determine how a BVS which has been deployed according to the IFU performs in these ACS patients. There is no comparator arm. Mandate that patients included in this registry follow a strict BVS implantation protocol which is felt to mitigate the not insignificant stent thrombosis rates noted with BVS to date.

Publication types

  • Editorial
  • Comment

MeSH terms

  • Absorbable Implants
  • Everolimus
  • Humans
  • Italy
  • Prospective Studies
  • Prosthesis Design
  • ST Elevation Myocardial Infarction*
  • Treatment Outcome

Substances

  • Everolimus